Quote:I see a breakthrough on the clinical level for a drug with no real side effects that stops metastasis and provides PD-L1 upregulation, not a buyout. If you view our worth as a .24 cent stock and the buyout as offer at 3 times that, I must ask, what is your goal in that statement? Seems a bit odd!
Unfortunately, it is “odd”--and not a bit—to expect a bit of realism from investors who confuse their thinking with that of Pfizer and its generous stockowners. What you and I think is of no matter for them. They are not paying for our hopium. This is "the goal of my statement”!
Quote:I think Paxlovid was in the store a full two years before approval, so if Pfizer decides today that LL is the next coming, how is that for your approval argument?
And what if Pfizer does not decide that "LL is the next coming" either today or tomorrow? What is your goal? You don’t believe that LL can make it unless Pfizer get religion? You want to say that we can not last for another two years if we MUST?
1
CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
